To: Speaker Pelosi, Minority Leader McCarthy, Chairman Grassley, and Ranking Member Wyden:
"For the health and well-being of our patients, the Society urges Congress to act now to reduce prescription drug prices, including the price of insulin. We have carefully reviewed both H.R. 3 and the Senate Finance committee’s Prescription Drug Pricing Reduction Act of 2019 (S. 2543) and have identified a number of provisions that we believe that if implemented, will improve transparency and lower costs to both patients and the health care system and should be included in Congress’ final legislation. We also encourage Congress to ensure that any legislation to address drug pricing include provisions that protect patient access to medically-necessary pharmaceuticals and that provide patients transparency on out-of-pocket costs. It is important to include provisions related to pharmacy benefit managers (PBMs) in a final legislative package, since these play an important role in the price of prescription drugs to patients."
Read the House Letter Read the Senate Letter
We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.